| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8922507 | Clinical and Translational Radiation Oncology | 2017 | 6 Pages |
Abstract
Despite promising growth delay effects of nelfinavir in other tumour models and first clinical applications of this drug as anti-cancer agent, PC-3 prostate cancer cells express no or only minor sensitivity to nelfinavir treatment alone and no radiosensitizing effect in vitro or in vivo.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Steffi Liebscher, Lydia Koi, Steffen Löck, Michael H. Muders, Mechthild Krause,